CD8A and neoplasm: High‐dose IL‐2 is approved in cancer therapy, where it promotes tumour killing by activating NK cells and CD4+ and CD8+ effector T cells 12; however, pulmonary vascular leakage occurs as a side effect to this treatment 35.